"Virginia Cancer Specialists offers a dedicate team of medical oncologists, hematologists, oncology nurses, oncology pharmacists and a research department, all working on your behalf to provide comprehsensive, advanced cancer care in your community."

During the past decade, Virginia Cancer Specialists conducted 247 clinical trials. In the 10-year time frame, 247 clinical trials started and 72 clinical trials were completed, i.e. on average, 29.1% percent of trials that started reached the finish line to date. In the past 5 years, 137 clinical trials started and 49 clinical trials were completed. i.e. 35.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Virginia Cancer Specialists" #1 sponsor was "Hoffmann-La Roche" with 22 trials, followed by "Pfizer" with 11 trials sponsored, "Seagen Inc." with 11 trials sponsored, "Daiichi Sankyo, Inc." with 9 trials sponsored and "Novartis Pharmaceuticals" with 9 trials sponsored. Other sponsors include 229 different institutions and companies that sponsored additional 136 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Virginia Cancer Specialists" #1 collaborator was "Merck Sharp & Dohme LLC" with 10 trials as a collaborator, "AstraZeneca" with 8 trials as a collaborator, "Bristol-Myers Squibb" with 7 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 5 trials as a collaborator and "Daiichi Sankyo Co., Ltd." with 4 trials as a collaborator. Other collaborators include 60 different institutions and companies that were collaborators in the rest 57 trials.

According to Clinical.Site data, the most researched conditions in "Virginia Cancer Specialists" are "Breast Cancer" (23 trials), "Non-Small Cell Lung Cancer" (22 trials), "Carcinoma, Non-Small-Cell Lung" (18 trials), "Non Small Cell Lung Cancer" (18 trials) and "Non-small Cell Lung Cancer" (17 trials). Many other conditions were trialed in "Virginia Cancer Specialists" in a lesser frequency.

Most popular intervention types in "Virginia Cancer Specialists" are "Drug" (269 trials), "Biological" (25 trials), "Other" (12 trials), "Procedure" (5 trials) and "Combination Product" (2 trials). Other intervention types were less common.

The name of intervention was led by "Carboplatin" (25 trials), "Placebo" (20 trials), "Pembrolizumab" (19 trials), "Atezolizumab" (16 trials) and "Pemetrexed" (16 trials). Other intervention names were less common.

The vast majority of trials in "Virginia Cancer Specialists" are 275 trials for "All" genders, 18 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "Virginia Cancer Specialists". undefined are not yet recruiting, 87 are recruiting, 71 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 93 completed trials in Virginia Cancer Specialists, undefined suspended trials, and 38 terminated clinical trials to date.

Out of the total trials that were conducted in Virginia Cancer Specialists, 144 "Phase 1" clinical trials were conducted, 156 "Phase 2" clinical trials and 60 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 4 trials that are defined as “Not Applicable".